No dose-limiting toxicities were observed, other than reversible transaminitis
This is similar to results seen in much larger efficacy and safety studies in ITP, despite a higher dose of REVOLADE used in SAA2
Eight (19%) patients had a new cytogenic abnormality reported while on therapy, including 5 patients who had changes in chromosome 71
1. REVOLADE Core Data Sheet. Version 2.4. 17 June 2019.
2. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825.
Disclaimer: This is an international website for REVOLADE® (eltrombopag) and is intended
for health care professionals outside the US. If you are a US resident, please click on the US Residents
links at the top of this page. The information on this site is not country-specific and may contain
information that is outside the approved indications in the country in which you are located.
This is an international site for REVOLADE® (eltrombopag) and is intended for health care professionals outside the US.
The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country. Please contact your local Novartis representative for local prescribing information via https://www.novartis.com/our-company/contact-us.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)
US HCPs & Other Country-Specific
At right is a list of the countries that host a REVOLADE website based on local label and in a local language. They are intended for health care professionals (HCPs) only. If you are an HCP from one of the countries listed at right, click on your country’s link to be redirected to your country’s REVOLADE website.